Recent Finacing
Recent Raise
Jalon Therapeutics develops intracellular peptide decoys that block AAC-11 protein interactions, induce tumor-cell membranolysis, and target non-oncogene addiction networks; lead JRT39 is in advanced preclinical development.
Focus Areas
Total Raised
Funding round